Research programme: cancer therapeutics - NuCana

Drug Profile

Research programme: cancer therapeutics - NuCana

Alternative Names: Azacitidine ProTide - NuCana; Capecitabine ProTide - NuCana; Cladiribine ProTide - NuCana; Decitabine ProTide - NuCana; Fludarabine ProTide - NuCana; NUC 4545; NUC 5435; NUC 6285; NUC 7000; NUC 7738; NUC 8000; NUC 9324

Latest Information Update: 23 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardiff University
  • Developer NuCana
  • Class Nucleosides
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 23 Mar 2016 Preclinical development is ongoing in United Kingdom
  • 09 Nov 2015 Pharmacodynamics data from a preclinical study in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  • 02 May 2013 Early research in Cancer in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top